Login  /  Register  /  Search

Medical Alley Association serves the individuals and organizations that comprise Minnesota's health industry by influencing policy, fostering connections and providing critical intelligence to improve the quality of health around the world.

Medical Alley Association serves the individuals and organizations that comprise Minnesota's health industry by influencing policy, fostering connections and providing critical intelligence to improve the quality of health around the world.

Capitol News: 3/6/2017

We deliver solutions in the public policy arena. With a focus on patient access, innovation and economic growth, the Medical Alley Association delivers the education, information, proposals and solutions that drive public policy changes in Minnesota and Washington, DC.

Influence Intelligence Interactions


Sign up to Receive Capitol News Updates

Medical Alley Goes to Washington

Shaye Mandle and Genevieve Plumadore traveled to Washington this week to continue our strong advocacy for full repeal of the Medical Device Tax.  Medical Alley was represented at the annual AdvaMed Capitol Hill Fly-In to meet with members of Congress on our collective MedTech agenda which includes: device repeal, MDUFA Reauthorization, and overall struggles of the reimbursement climate.  

MAA met with members of the Minnesota delegation as well as key staff from the Trump/Pence administration.  Congressman Erik Paulsen addressed the group of med tech leaders at the AdvaMed headquarters and gave us a preview of the road ahead for repeal. 

Being on Capitol Hill amidst an administration change was very exciting!  There were countless other stakeholders and citizen groups advocating for change on behalf of their constituencies.  The Capitol was buzzing!  Coincidentally, we were also in D.C. for the State of the State address--- which brought with it tightened security lines and road closures.  Exciting! 

The trip was nicely rounded off with productive meetings with Senator Franken, Congressman Tom Emmer, Congressman Lewis, and other key staff representing Minnesota’s Medical Alley.  

Fly In

Fly In 2

Fly In 3

Al Franken

Fly In 4

Fly In 5

Fly In 6

 


Minnesota Management and Budget (MMB) Releases February Economic Forecast, Governor Dayton Cautiously Optimistic

Earlier this week, representatives from MMB, as well as Governor Dayton, presented the February economic forecast. Currently, the state has a projected $1.65B surplus, which rises to $2B when including cash and budget reserves.

MMB Commissioner Myron Frans and other representatives of the department emphasized Minnesota’s modest and steady growth, robust and diverse economy, and consumer confidence. The state is in its 8th consecutive report of positive growth.

Nationally, U.S. economic outcomes look generally positive, and current fiscal policy is expected to boost consumer spending. In MN, higher wage growth than expected is due in part to growing industry, more job openings than applicants, and higher projected corporate profits. MN outperforms the rest of the nation in growth, and has a lower unemployment rate than average.

Commissioner Frans noted in spite of the positives, significant risks with the February forecast, including uncertainty across the U.S. on fiscal policy, international trade, inflation, and slow-growth expansion as well as shake-ups in direction from the new presidential administration. 

Governor Dayton echoed many of his colleagues’ points on the budget, risks, and the positives. Among them, he highlighted MN’s rankings as #3 best state by U.S. News & World Report, its AAA Fitch rating, #2 Best-Run State by 24/7 Wall St, and Best State for Job Creation by Gallup. However, Dayton ended on a cautious note, and warned that in spite of a positive outlook, his Republican colleagues in the legislature should work with him to keep MN’s budget “structurally balanced.”


As Session Moves Forward, Committee Deadlines Approach

Each year, thousands of bills are drafted and introduced in the House and Senate. This year alone, almost 2,000 bills were introduced in the Senate, and 1,700 in the House. After being introduced, bills are referred to relevant committees for possible consideration on the legislative floor.

Because of the staggering amount of bills that are introduced, not every bill gets a hearing, and not every bill gets to the legislative floor. Instead, committees choose which bills move forward, and committee deadlines are put in place to make sure that all bills wanting to be considered are submitted by a specified date so they can be put through the process in a timely manner.

This year, all of the committee deadlines fall in March for this session.

The deadlines are as follows:

  • March 10, 2017, by midnight for bills being introduced in the bills body of origin (Senate or House)
  • March 17, 2017, by midnight for bills, or companions of bills that met first deadline in the other body (Senate or House)
  • March 31, 2017, by midnight for bills from either body dealing with major appropriations or finance

The exception is that the deadlines do not apply to House committees on Capitol Investment, Taxes, Finance, Ways and Means and Legislative Administration. In the Senate, the exceptions are Capitol Investment, Finance, Taxes, or Rules and Administration.


MnDRIVE Included in University of Minnesota Legislative Ask

The University of Minnesota testified in both House and Senate committees this week as they made their case before legislators for state funding to advance the university’s initiatives.

Among these initiatives was $32M in funding for MnDRIVE, a university program that aims to fund and expand a network for clinical trial cancer drug trials for Minnesotans outside of MSP. The program would benefit those residing in Greater MN by expanding accessibility to treatment sites.  For more information on the proposal please visit this site: https://www.med.umn.edu/cancertrials


President Trump Addresses Joint Session of Congress, Highlights Need for FDA to Expedite Approval Process

The President addressed Congress in a joint session on Tuesday night, laying out his vision for his administration for the next four years, and urging Congress to take action on issues important to Americans.

Relating to healthcare, President Trump criticized the U.S. Food and Drug Administration’s (FDA) “slow and burdensome approval process,” and promised to “slash restraints, not just at the FDA, but across our government.”

Minnesota U.S. House members from both sides of the aisle responded to the President’s address with mixed reviews. Republican Congressman Erik Paulsen from the 3rd District said, “There were many encouraging aspects in the President’s speech … I was especially pleased to hear the President emphasize the importance of FDA reform to spur medical innovation and research … to spur medical innovation and develop life-saving technology,”

However, others were not as optimistic, such as Democratic Congressman Rick Nolan from the 8th District. “The President made some great promises to support fair trade … and bipartisanship – but the problem is we can’t believe him, because at one point or another he’s been on every side of every issue. Hopefully President Trump will be true to his rhetoric and join us in supporting these initiatives,” said Nolan.

See Other Capitol News